



OFSEP

Observatoire Français
de la Sclérose en Plaques

MSPARIS2017

OFSEP scientific presentations at a glance

OFSEP researchers will be present at MS Paris 2017. Come and hear about their work! You can also meet the OFSEP coordination team at **EDMUS stand, no. D86**. We look forward to seeing you there!

Thursday, 26 October 2017

10:45 - 12:15 Parallel session 2: The new MS criteria - Hall A

Comparative evaluation of successive criteria for neuromyelitis optica.
R. Marignier, Lyon, FR

15:30 - 17:00 Poster session 1

- P296** Double seronegative longitudinally extensive transverse myelitis: preliminary study on 17 patients. E. Maillart, Paris, FR
- P301** Myelin oligodendrocyte glycoprotein antibodies predict a favourable outcome in neuromyelitis optica related disorders. A. Cobo-Calvo, Lyon, FR
- P302** Myelin oligodendrocyte glycoprotein antibodies spectrum disorder: clinical features and prognostic factors in a cohort of 150 adult patients. A. Cobo-Calvo, Lyon, FR
- P303** Prognostic factor for therapeutic response of attacks in anti-AQP4, anti-MOG seropositive and NMO seronegative patients. N. Collongues, Strasbourg, FR
- P323** Characteristics of radiologically isolated syndrome (RIS) national French cohort. C. Lebrun-Frenay, Nice, FR
- P335** Observatoire Français de la Sclérose en Plaques (OFSEP): a powerful epidemiological tool. R. Casey, Lyon, FR
- P738** Big Multiple Sclerosis Data network: data sharing among five large MS registries. P. Iaffaldano, Bari, IT

15:30 - 17:00 Poster session 2

- P1149** Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France. X. Ayrignac, Montpellier, FR
- P1154** Efficacy of rituximab as a rescue therapy after the failure of second line treatment in relapsing remitting multiple sclerosis: a retrospective observational monocenter study. P. Durozard, Marseille, FR
- P1237** Disease-modifying therapies use in primary progressive multiple sclerosis patients in France: data from the OFSEP cohort over the 1996 - 2017 period. E. Leray, Rennes, FR

ePosters

ePosters will be displayed on terminals during the congress and will also be available on the ECTRIMS Online Library.

- EP1302** Atypical Multiple Sclerosis and Idiopathic Inflammatory Demyelinating Diseases in a series of 74 consecutive cases. P. Labauge, Montpellier, FR
- EP1335** Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France: data from the OFSEP database over the period 1996-2017. E. Leray, Rennes, FR
- EP1555** OFSEP MRI protocol: the need of good practice's standardization from clinicians to scientists. F. Cotton, Lyon, FR
- EP1612** OFSEP biobank: high quality samples for powerful research on MS biomarkers. N. Dufay, Lyon, FR
- EP1618** Two-year follow-up of 19 patients treated with alemtuzumab for active relapsing-remitting MS: the Lyon's experience. F. Durand Dubief, FR
- EP1622** Comparative efficacy of Teriflunomide versus Dimethyl-Fumarate: a French multicenter observational study from the french national OFSEP cohort. D. Laplaud, Nantes, FR

Going further

*Do you want to look at the cohort description?
Flash the QR code opposite or go to our website:
www.ofsep.org/en/cohort/cohort-description*

